

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
CIN: L24230GJ1993PLC019050



September 25, 2020

National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051,
Maharashtra, India.

BSE Limited

1st Floor, P. J. Towers,
Dalal Street, Mumbai – 400 001,
Maharashtra, India.

Scrip Symbol: SUNPHARMA

Scrip Code: 524715

Dear Sir / Madam,

Subject: Intimation of closure of Buy-back period for buy-back of Equity Shares by Sun Pharmaceutical Industries Limited (“Company”) in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

We refer to the public announcement dated March 18, 2020 (“**Public Announcement**”) read with Corrigendum to Public Announcement dated March 24, 2020 (“**Corrigendum**”) whereby the Company had announced the buy-back of fully paid-up equity shares of the Company having face value of Re. 1/- (“**Equity Share**”) from the Open Market through stock exchange mechanism as prescribed under the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018 (“**Buy-back Regulations**”) at a maximum price of Rs. 425/- (Rupees Four Hundred Twenty Five Only) per Equity Share (“**Maximum Buy-back Price**”) payable in cash, for an aggregate maximum amount of up to Rs. 1700,00,00,000/- (Rupees One Thousand Seven Hundred Crores Only) excluding transaction costs viz. brokerage, advisor’s fees, intermediaries fees, public announcement, publication fees, filing fees, turnover charges, applicable taxes such as securities transaction tax, goods and services tax, income tax, stamp duty and other incidental and related expenses.

In terms of the Public Announcement read with Corrigendum, the Buy-back commenced from Thursday, March 26, 2020 and the last date for the completion of Buy-Back would be Friday, September 25, 2020 i.e. within 6 months from the date of opening of Buy-back. Therefore, the Buy-back of Equity Shares by the Company stands closed effective from closure of trading hours today, i.e., Friday, September 25, 2020.

No Equity Shares have been bought back under the Buy-back as the volume weighted average market price of Equity Shares of the Company during the Buy-Back period was higher than the Maximum Buy-back Price.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
CIN: L24230GJ1993PLC019050



The pre Buy-back and post Buy-back summarized shareholding pattern of the Company is enclosed herewith as **Annexure - A**.

Kindly take this disclosure on record and disseminate this information to the public.

Thanking you,

Yours faithfully,

For Sun Pharmaceutical Industries Limited

Ashok I. Bhuta
Compliance Officer

Encl.: As above

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
CIN: L24230GJ1993PLC019050



Annexure - A

Pre Buy-back and post Buy-back summarized shareholding pattern of the Company

Category of Shareholder	Pre Buy-back [#]		Post Buy-back	
	Number of equity share held	% to the equity share capital	Number of equity share held	% to the equity share capital
(A) Promoter and Promoter Group	1,31,21,34,535	54.69	1,31,21,34,535	54.69
(B) Public Shareholders				
Institutions	77,44,34,761	32.28	1,08,72,00,435	45.31
Central Government / State Government(s) / President of India	6,430	0.00		
Non-Institutions	31,27,59,244	13.03		
Sub-Total	1,08,72,00,435	45.31		
(C) Non Promoter – Non Public	Nil	Nil	Nil	Nil
Total	2,39,93,34,970	100.00	2,39,93,34,970	100.00

As on March 17, 2020 viz. the date of Board Meeting approving Buy-back.

For Sun Pharmaceutical Industries Limited

Ashok I. Bhuta
Compliance Officer